Trial · NCT05416515
A Study of Fisetin to Treat Carpal Tunnel Syndrome
NCT05416515, Phase 2, Completed, Peter C. Amadio, M.D.; results first posted 2025-12-24
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study of Fisetin to Treat Carpal Tunnel Syndrome. Trials, record NCT05416515. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05416515
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study of Fisetin to Treat Carpal Tunnel Syndrome
- NCT number
- NCT05416515
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 40 participants, actual
- Lead sponsor
- Peter C. Amadio, M.D.
- Conditions
- Carpal Tunnel Syndrome
- Interventions
- Fisetin
- First posted
- 2022-06-13
- Last updated
- 2025-12-24
- Results first posted
- 2025-12-24
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Boston Carpal Tunnel Syndrome (BCTQ) Score | Baseline, 60 days | The Boston Carpal Tunnel Syndrome questionnaire (BCTQ) assesses symptom severity and overall function of subjects with Carpel Tunnel Syndrome. The questionnaire consists of two sections: 1. Symptom Severity (11 questions) and 2. Functional Status (8 questions). Subjects are asked to rate each question on a scale of 1 to 5. The mean score for each section is calculated by summing the individual question responses and diving by the number of questions resulting in a total score ranging from 1 to 5, with higher scores indicating greater symptom severity and dysfunction. |
| Secondary | Percent Decrease in Blood Markers of Cellular Senescence, e.g., p16, IL-6, IL-15, TNF, PAI-1, ICAM-1, and Additional Exploratory, Novel Assays | Baseline, 60 days | Blood samples collected to measure percent decrease in circulating blood biomarkers of senescence |
| Secondary | Percent Decrease in Blood Markers of Cellular Senescence in Long-term | Baseline, 180 days | percent decrease in blood markers of cellular senescence, e.g., p16, IL-6, IL-15, TNF, PAI-1, ICAM-1, and additional exploratory, novel assays |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change in Boston Carpal Tunnel Syndrome (BCTQ) Score | Baseline, 60 days | score on a scale | MEAN | |
| SECONDARY | Percent Decrease in Blood Markers of Cellular Senescence, e.g., p16, IL-6, IL-15, TNF, PAI-1, ICAM-1, and Additional Exploratory, Novel Assays | Baseline, 60 days | |||
| SECONDARY | Percent Decrease in Blood Markers of Cellular Senescence in Long-term | Baseline, 180 days |
Source ClinicalTrials.gov
Results by group1
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change in Boston Carpal Tunnel Syndrome (BCTQ) Score | Carpal Tunnel Syndrome | -0.5 | Standard Deviation 0.6 | score on a scale |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Carpal Tunnel Syndrome | 40 | |
| Overall Study | COMPLETED | Carpal Tunnel Syndrome | 40 | |
| Overall Study | NOT COMPLETED | Carpal Tunnel Syndrome | 0 |
Source ClinicalTrials.gov
Adverse events8
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Weight Gain | Investigations | Carpal Tunnel Syndrome | 1 | 40 | |
| other | Loose Bowels | Gastrointestinal disorders | Carpal Tunnel Syndrome | 1 | 40 | |
| other | Increased Pain | General disorders | Carpal Tunnel Syndrome | 7 | 40 | |
| other | Surgery due to Continued Pain | General disorders | Carpal Tunnel Syndrome | 6 | 40 | |
| other | C-Reactive Protein Level Increased | Investigations | Carpal Tunnel Syndrome | 1 | 40 | |
| other | Increased Symptom Severity | General disorders | Carpal Tunnel Syndrome | 5 | 40 | |
| other | Leg Cramping | Musculoskeletal and connective tissue disorders | Carpal Tunnel Syndrome | 1 | 40 | |
| other | Headaches | Nervous system disorders | Carpal Tunnel Syndrome | 1 | 40 |
Source ClinicalTrials.gov
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Carpal Tunnel Syndrome | 0 | 40 |
| Total, other adverse events | Carpal Tunnel Syndrome | 15 | 40 |
| Total, serious adverse events | Carpal Tunnel Syndrome | 0 | 40 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05416515
GET https://conductscience.org/api/trials/v1/NCT05416515/registered